Literature DB >> 30486661

Edoxaban for Venous Thromboembolism Treatment-The New Kid on The Block for Latin America. A Practical Guide.

Eduardo Ramacciotti1,2,3, Valéria Cristina Resende Aguiar2, Valter Castelli Júnior1, Ivan Benaducce Casella4, Antonio Eduardo Zerati4, Jawed Fareed3.   

Abstract

Edoxaban, a direct factor Xa inhibitor (FXa), is the fourth direct oral anticoagulant (DOAC) approved for clinical use in the treatment of venous thromboembolism (VTE) in Latin America, following global approvals for this indication. Edoxaban features some particular characteristics when compared to the previously approved DOACs. This review summarizes the main properties of edoxaban, the outcomes results of its pivotal global clinical trials and the peculiar clinical features of this compound. This practical guide aims to help Latin America clinicians understand edoxaban, its proper indication and its use for the appropriate patients with VTE.

Entities:  

Keywords:  edoxaban; non-vitamin K antagonist oral anticoagulants; oral anticoagulants; venous thromboembolism; vitamin K antagonists

Mesh：

Substances：

Year:  2018        PMID： 30486661      PMCID： PMC6714848          DOI： 10.1177/1076029618812955

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN： 1076-0296            Impact factor:   2.389


  33 in total

Review 1.  A Comprehensive Overview of Direct Oral Anticoagulants for the Management of Venous Thromboembolism.

Authors:  Anthony J Comerota; Eduardo Ramacciotti
Journal:  Am J Med Sci       Date:  2016-04-06       Impact factor: 2.378

2.  Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

Authors:  Harry R Büller; Hervé Décousus; Michael A Grosso; Michele Mercuri; Saskia Middeldorp; Martin H Prins; Gary E Raskob; Sebastian M Schellong; Lee Schwocho; Annelise Segers; Minggao Shi; Peter Verhamme; Phil Wells
Journal:  N Engl J Med       Date:  2013-08-31       Impact factor: 91.245

Review 3.  Management of Pulmonary Embolism: An Update.

Authors:  Stavros V Konstantinides; Stefano Barco; Mareike Lankeit; Guy Meyer
Journal:  J Am Coll Cardiol       Date:  2016-03-01       Impact factor: 24.094

4.  Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate.

Authors:  Hamim Zahir; Karen S Brown; Alexander G Vandell; Madhuri Desai; Jen-Fue Maa; Victor Dishy; Barbara Lomeli; Annette Feussner; Wenqin Feng; Ling He; Michael A Grosso; Hans J Lanz; Elliott M Antman
Journal:  Circulation       Date:  2014-11-17       Impact factor: 29.690

5.  Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists.

Authors:  Marjolein P A Brekelmans; Suzanne M Bleker; Rupert Bauersachs; Zoltan Boda; Harry R Büller; Youngsook Choi; Alex Gallus; Michael A Grosso; Saskia Middeldorp; Doyeun Oh; Gary Raskob; Lee Schwocho; Alexander T Cohen
Journal:  Thromb Haemost       Date:  2016-03-24       Impact factor: 5.249

6.  DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles.

Authors:  T Furugohri; K Isobe; Y Honda; C Kamisato-Matsumoto; N Sugiyama; T Nagahara; Y Morishima; T Shibano
Journal:  J Thromb Haemost       Date:  2008-07-04       Impact factor: 5.824

7.  Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials.

Authors:  G Raskob; H Büller; M Prins; A Segers; M Shi; L Schwocho; R van Kranen; M Mercuri
Journal:  J Thromb Haemost       Date:  2013-07       Impact factor: 5.824

Review 8.  Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.

Authors:  A T Cohen; M Hamilton; S A Mitchell; H Phatak; X Liu; A Bird; D Tushabe; S Batson
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

Review 9.  Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide.

Authors:  Raffaele De Caterina; Walter Ageno; Giuseppe Boriani; Paolo Colonna; Angelo Ghirarduzzi; Giuseppe Patti; Roberta Rossini; Andrea Rubboli; Piercarla Schinco; Giancarlo Agnelli
Journal:  Adv Ther       Date:  2017-02-13       Impact factor: 3.845

10.  Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model.

Authors:  Genmin Lu; Polly Pine; Janet M Leeds; Francis DeGuzman; Pratikhya Pratikhya; Joyce Lin; John Malinowski; Stanley J Hollenbach; John T Curnutte; Pamela B Conley
Journal:  PLoS One       Date:  2018-03-28       Impact factor: 3.240
View more
  1 in total

Review 1.  Direct Oral Anticoagulants for the Treatment of Cancer-Associated Venous Thromboembolism: A Latin American Perspective.

Authors:  Rodrigo Abensur Athanazio; José Manuel Ceresetto; Luis Javier Marfil Rivera; Gabriela Cesarman-Maus; Kenny Galvez; Marcos Arêas Marques; Aldo Hugo Tabares; Carlos Alberto Ortiz Santacruz; Fernando Costa Santini; Luis Corrales; Alexander T Cohen
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 2.389
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.